Modality
mAb
MOA
MALT1i
Target
RET
Pathway
Epigenetic
Huntington's
Development Pipeline
Preclinical
~Jan 2021
→ ~Apr 2022
Phase 1
Jul 2022
→ Aug 2027
Phase 1Current
NCT07615616
1,126 pts·Huntington's
2022-07→2027-08·Terminated
NCT03250442
416 pts·Huntington's
2025-10→2026-03·Not yet recruiting
1,542 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-07-218mo agoBTD· Huntington's
2026-03-256d agoInterim· Huntington's
2027-08-051.3y awayInterim· Huntington's
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P1
Termina…
P1
Not yet…
Catalysts
BTD
2025-07-21 · 8mo ago
Huntington's
Interim
2026-03-25 · 6d ago
Huntington's
Interim
2027-08-05 · 1.3y away
Huntington's
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07615616 | Phase 1 | Huntington's | Terminated | 1126 | HbA1c |
| NCT03250442 | Phase 1 | Huntington's | Not yet recr... | 416 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| RHH-5389 | Roche | Preclinical | RET | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| VRT-1576 | Vertex Pharma | Phase 2/3 | RET | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 |